Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00143611




Registration number
NCT00143611
Ethics application status
Date submitted
31/08/2005
Date registered
2/09/2005
Date last updated
2/02/2012

Titles & IDs
Public title
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis
Scientific title
A Pivotal, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety of TAK-242 in Adults With Severe Sepsis
Secondary ID [1] 0 0
2005-003561-16
Secondary ID [2] 0 0
01-04-TL-242-011
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Sepsis 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Injuries and Accidents 0 0 0 0
Poisoning
Blood 0 0 0 0
Other blood disorders
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Resatorvid
Treatment: Drugs - Resatorvid
Treatment: Drugs - Placebo

Experimental: Resatorvid 1.2 mg/kg/day -

Experimental: Resatorvid 2.4 mg/kg/day -

Placebo comparator: Placebo -


Treatment: Drugs: Resatorvid
Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.

Treatment: Drugs: Resatorvid
Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.

Treatment: Drugs: Placebo
Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
28-day All-cause Mortality.
Timepoint [1] 0 0
Day 28
Secondary outcome [1] 0 0
Change from Baseline in Organ Failure Assessment
Timepoint [1] 0 0
Day 28
Secondary outcome [2] 0 0
Mean Systemic Inflammatory Response
Timepoint [2] 0 0
Day 28
Secondary outcome [3] 0 0
Mean Vasopressor-free days
Timepoint [3] 0 0
Day 28
Secondary outcome [4] 0 0
Mean Ventilator-free days
Timepoint [4] 0 0
Day 28
Secondary outcome [5] 0 0
Mean Intensive Care Unit free days
Timepoint [5] 0 0
Day 28
Secondary outcome [6] 0 0
Mean Discharge Status.
Timepoint [6] 0 0
Day 28

Eligibility
Key inclusion criteria
* Has clinical evidence of infection defined as the presence of a known or probable source of infection requiring the initiation of parenteral antimicrobial therapy.
* Must meet at least 3 of the following 4 criteria for SIRS:

* A core temperature greater than 38°C or less than 36°C.
* A heart rate greater than 90 beats per minute.
* A respiratory rate greater than 20 breaths/min or partial pressure of carbon dioxide in arterial blood less than 32 mm Hg or mechanical ventilation for an acute process.
* A total white blood cell absolute count greater than 12,000 cells/mm3 or less than 4,000 cells/mm3, or a white blood cell differential count that showed greater than 10% immature (band) forms.
* Must have sepsis with shock and/or respiratory failure.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* If female, the subject is pregnant, nursing and the milk is intended to be ingested by the infant, or the participant plans to become pregnant, or nurse and the milk is intended to be ingested by the infant.
* Is receiving immunosuppressive therapy such as cyclosporine, azathioprine, or cancer-related chemotherapy.
* Has a granulocyte count of less than 1000/mm3 except if the decreased count was believed to be due to sepsis.
* Has documented or suspected acute myocardial infarction within the last 6 weeks prior to Pretreatment Period.
* Has a documented history of moderate to severe chronic heart failure as defined by New York Heart Association Functional Classification III or IV.
* Is known to be positive for human immunodeficiency virus with known CD4 count less than or equal to 50/mm3 or had known end-stage processes.
* Has a known history of glucose-6-phosphate dehydrogenase deficiency.
* Has a methemoglobin level greater than 5% at Pretreatment Period or had a known history of methemoglobinemia.
* Is moribund and death was considered imminent.
* Is classified as "Do Not Resuscitate", or "Do Not Treat", or the participant's family has not committed to aggressive management of the participant's condition.
* Is not expected to survive for 28 days and was not likely be given life support due to a pre-existing, uncorrectable medical condition.
* Has a known esophageal varices, chronic jaundice, cirrhosis, or chronic ascites.
* Is in a chronic vegetative state or has a similar long-term neurological condition.
* Has known portal hypertension or Child-Pugh hepatic impairment class C.
* Has acute third degree burns involving more than 30% of body surface within 120 hours prior to Pretreatment Period.
* Has known hypersensitivity to sulfonamides.
* Has known hypersensitivity to components of resatorvid.
* Has participated in any other investigational study (drug or device) and/or taken any investigational drug within 30 days or 5 half-lives of the drug.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2007
Sample size
Target
Accrual to date
Final
277
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Fremantle
Recruitment hospital [3] 0 0
- Heidelberg
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Fremantle
Recruitment postcode(s) [3] 0 0
- Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Delaware
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Iowa
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maine
Country [15] 0 0
United States of America
State/province [15] 0 0
Maryland
Country [16] 0 0
United States of America
State/province [16] 0 0
Massachusetts
Country [17] 0 0
United States of America
State/province [17] 0 0
Michigan
Country [18] 0 0
United States of America
State/province [18] 0 0
Missouri
Country [19] 0 0
United States of America
State/province [19] 0 0
Montana
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
South Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
Tennessee
Country [27] 0 0
United States of America
State/province [27] 0 0
Texas
Country [28] 0 0
United States of America
State/province [28] 0 0
Washington
Country [29] 0 0
Austria
State/province [29] 0 0
Linz
Country [30] 0 0
Austria
State/province [30] 0 0
Wien
Country [31] 0 0
Belgium
State/province [31] 0 0
Aalst
Country [32] 0 0
Belgium
State/province [32] 0 0
Antwerpen
Country [33] 0 0
Belgium
State/province [33] 0 0
Brussel
Country [34] 0 0
Belgium
State/province [34] 0 0
Bruxelles
Country [35] 0 0
Belgium
State/province [35] 0 0
Genk
Country [36] 0 0
Belgium
State/province [36] 0 0
Gent
Country [37] 0 0
Belgium
State/province [37] 0 0
Liege
Country [38] 0 0
Belgium
State/province [38] 0 0
Ottignies
Country [39] 0 0
Belgium
State/province [39] 0 0
Yvoir
Country [40] 0 0
Canada
State/province [40] 0 0
Alberta
Country [41] 0 0
Canada
State/province [41] 0 0
British Columbia
Country [42] 0 0
Canada
State/province [42] 0 0
Manitoba
Country [43] 0 0
Canada
State/province [43] 0 0
Nova Scotia
Country [44] 0 0
Canada
State/province [44] 0 0
Ontario
Country [45] 0 0
Czech Republic
State/province [45] 0 0
Brno
Country [46] 0 0
Czech Republic
State/province [46] 0 0
Havlickuv Brod
Country [47] 0 0
Czech Republic
State/province [47] 0 0
Hradec Kralove
Country [48] 0 0
Czech Republic
State/province [48] 0 0
Opava
Country [49] 0 0
Czech Republic
State/province [49] 0 0
Pilsen
Country [50] 0 0
Czech Republic
State/province [50] 0 0
Prague
Country [51] 0 0
Finland
State/province [51] 0 0
Helsinki
Country [52] 0 0
Finland
State/province [52] 0 0
Joensuu
Country [53] 0 0
Finland
State/province [53] 0 0
Kokkola
Country [54] 0 0
Finland
State/province [54] 0 0
Kuopio
Country [55] 0 0
Finland
State/province [55] 0 0
Lappeenranta
Country [56] 0 0
Finland
State/province [56] 0 0
Oulu
Country [57] 0 0
Finland
State/province [57] 0 0
Seinajoki
Country [58] 0 0
Finland
State/province [58] 0 0
Tampere
Country [59] 0 0
Finland
State/province [59] 0 0
Turku
Country [60] 0 0
Germany
State/province [60] 0 0
Berlin
Country [61] 0 0
Germany
State/province [61] 0 0
Dresden
Country [62] 0 0
Germany
State/province [62] 0 0
Erfurt
Country [63] 0 0
Germany
State/province [63] 0 0
Jena
Country [64] 0 0
Germany
State/province [64] 0 0
Krefeld
Country [65] 0 0
Germany
State/province [65] 0 0
Ludwigshafen
Country [66] 0 0
Germany
State/province [66] 0 0
Mannheim
Country [67] 0 0
Germany
State/province [67] 0 0
Munchen
Country [68] 0 0
Germany
State/province [68] 0 0
Wuppertal
Country [69] 0 0
Israel
State/province [69] 0 0
Afula
Country [70] 0 0
Israel
State/province [70] 0 0
Ashkelon
Country [71] 0 0
Israel
State/province [71] 0 0
Haifa
Country [72] 0 0
Israel
State/province [72] 0 0
Holon
Country [73] 0 0
Israel
State/province [73] 0 0
Jerusalem
Country [74] 0 0
Israel
State/province [74] 0 0
Kfar Saba
Country [75] 0 0
Israel
State/province [75] 0 0
Petach-Tikva
Country [76] 0 0
Israel
State/province [76] 0 0
Zerifin
Country [77] 0 0
Italy
State/province [77] 0 0
Lecco
Country [78] 0 0
Italy
State/province [78] 0 0
Monza
Country [79] 0 0
Italy
State/province [79] 0 0
Pavia
Country [80] 0 0
Japan
State/province [80] 0 0
Chiba
Country [81] 0 0
Japan
State/province [81] 0 0
Fukuoka
Country [82] 0 0
Japan
State/province [82] 0 0
Hiroshima
Country [83] 0 0
Japan
State/province [83] 0 0
Hokkaido
Country [84] 0 0
Japan
State/province [84] 0 0
Iwate
Country [85] 0 0
Japan
State/province [85] 0 0
Kumamoto
Country [86] 0 0
Japan
State/province [86] 0 0
Kyoto
Country [87] 0 0
Japan
State/province [87] 0 0
Osaka
Country [88] 0 0
Japan
State/province [88] 0 0
Shizuoka
Country [89] 0 0
Japan
State/province [89] 0 0
Tokyo
Country [90] 0 0
Japan
State/province [90] 0 0
Yamaguchi
Country [91] 0 0
Netherlands
State/province [91] 0 0
Apeldoorn
Country [92] 0 0
Netherlands
State/province [92] 0 0
Groningen
Country [93] 0 0
Netherlands
State/province [93] 0 0
Leeuwarden
Country [94] 0 0
Netherlands
State/province [94] 0 0
Nijmegen
Country [95] 0 0
Netherlands
State/province [95] 0 0
Rotterdam
Country [96] 0 0
Netherlands
State/province [96] 0 0
s-Hertogenbosch
Country [97] 0 0
Netherlands
State/province [97] 0 0
Tilburg
Country [98] 0 0
New Zealand
State/province [98] 0 0
Auckland
Country [99] 0 0
New Zealand
State/province [99] 0 0
Christchurch
Country [100] 0 0
New Zealand
State/province [100] 0 0
Hastings
Country [101] 0 0
New Zealand
State/province [101] 0 0
Tauranga
Country [102] 0 0
Puerto Rico
State/province [102] 0 0
San Juan
Country [103] 0 0
Spain
State/province [103] 0 0
Barcelona
Country [104] 0 0
Spain
State/province [104] 0 0
Getafe
Country [105] 0 0
Spain
State/province [105] 0 0
Madrid
Country [106] 0 0
Spain
State/province [106] 0 0
Valladolid
Country [107] 0 0
Spain
State/province [107] 0 0
Vitoria
Country [108] 0 0
Sweden
State/province [108] 0 0
Gavle
Country [109] 0 0
Sweden
State/province [109] 0 0
Goteborg
Country [110] 0 0
Sweden
State/province [110] 0 0
Karlstad
Country [111] 0 0
Sweden
State/province [111] 0 0
Kristianstad
Country [112] 0 0
Sweden
State/province [112] 0 0
Linkoping
Country [113] 0 0
Sweden
State/province [113] 0 0
Lund
Country [114] 0 0
Sweden
State/province [114] 0 0
Stockholm
Country [115] 0 0
Sweden
State/province [115] 0 0
Uppsala
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Brighton
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Glasgow
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Leeds
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Livingston
Country [120] 0 0
United Kingdom
State/province [120] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Takeda
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
VP Clinical Science
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

TypeCitations or Other Details
Journal Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus... [More Details]

Results not provided in https://clinicaltrials.gov/study/NCT00143611